181 related articles for article (PubMed ID: 36920298)
1. [How to cope with the nocebo effects of statins?].
Lafeber M; Evers AWM; Klok FA
Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36920298
[TBL] [Abstract][Full Text] [Related]
2. The nocebo effect in the context of statin intolerance.
Tobert JA; Newman CB
J Clin Lipidol; 2016; 10(4):739-747. PubMed ID: 27578103
[TBL] [Abstract][Full Text] [Related]
3. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.
Penson PE; Mancini GBJ; Toth PP; Martin SS; Watts GF; Sahebkar A; Mikhailidis DP; Banach M;
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1023-1033. PubMed ID: 30311434
[TBL] [Abstract][Full Text] [Related]
4. SAMSON and the Nocebo Effect: Management of Statin Intolerance.
Krishnamurthy A; Bradley C; Ascunce R; Kim SM
Curr Cardiol Rep; 2022 Sep; 24(9):1101-1108. PubMed ID: 35759168
[TBL] [Abstract][Full Text] [Related]
5. Muscle and statins: from toxicity to the nocebo effect.
Pedro-Botet J; Climent E; Benaiges D
Expert Opin Drug Saf; 2019 Jul; 18(7):573-579. PubMed ID: 31070941
[TBL] [Abstract][Full Text] [Related]
6. Management of patients with statin intolerance.
Martirossian AN; Goldberg AC
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101714. PubMed ID: 36345572
[TBL] [Abstract][Full Text] [Related]
7. New insights into managing symptoms during statin therapy.
Robinson JG
Prog Cardiovasc Dis; 2019; 62(5):390-394. PubMed ID: 31669768
[TBL] [Abstract][Full Text] [Related]
8. Statins and muscle pain.
Pergolizzi JV; Coluzzi F; Colucci RD; Olsson H; LeQuang JA; Al-Saadi J; Magnusson P
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):299-310. PubMed ID: 32089020
[No Abstract] [Full Text] [Related]
9. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment.
Howard JP; Wood FA; Finegold JA; Nowbar AN; Thompson DM; Arnold AD; Rajkumar CA; Connolly S; Cegla J; Stride C; Sever P; Norton C; Thom SAM; Shun-Shin MJ; Francis DP
J Am Coll Cardiol; 2021 Sep; 78(12):1210-1222. PubMed ID: 34531021
[TBL] [Abstract][Full Text] [Related]
10. Examining the Nocebo Effect of Statins Through Statin Adverse Events Reported in the Food and Drug Administration Adverse Event Reporting System.
Moon J; Cohen Sedgh R; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Jan; 14(1):e007480. PubMed ID: 33161769
[TBL] [Abstract][Full Text] [Related]
11. [Muscle pain and statin, pharmacological or nocebo effect?].
Khouri C; Lepelley M; Mallaret M; Roustit M; Cracowski JL
Therapie; 2018 Sep; 73(4):359-361. PubMed ID: 29366501
[No Abstract] [Full Text] [Related]
12. A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms.
Orringer CE; Grant JK; Tokgozoglu L
Curr Atheroscler Rep; 2022 Nov; 24(11):839-847. PubMed ID: 36001213
[TBL] [Abstract][Full Text] [Related]
13. Statins in a Distorted Mirror of Media.
Nelson AJ; Puri R; Nissen SE
Curr Atheroscler Rep; 2020 Jun; 22(8):37. PubMed ID: 32557172
[TBL] [Abstract][Full Text] [Related]
14. Advances in the management of statin myopathy.
Gallo A; Perregaux J; Bruckert E
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):142-151. PubMed ID: 33278129
[TBL] [Abstract][Full Text] [Related]
15. [Myalgia and statins: Separating the true from the false].
Blacher J; Bruckert E; Farnier M; Ferrières J; Henry P; Krempf M; Mourad JJ
Presse Med; 2019 Oct; 48(10):1059-1064. PubMed ID: 31473026
[TBL] [Abstract][Full Text] [Related]
16. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
[TBL] [Abstract][Full Text] [Related]
17. "Important Conversations" Are Needed to Explain the Nocebo Effect.
Slomski A
JAMA; 2021 Feb; 325(8):707-709. PubMed ID: 33533926
[No Abstract] [Full Text] [Related]
18. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
[TBL] [Abstract][Full Text] [Related]
19. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient.
Cheeley MK; Saseen JJ; Agarwala A; Ravilla S; Ciffone N; Jacobson TA; Dixon DL; Maki KC
J Clin Lipidol; 2022; 16(4):361-375. PubMed ID: 35718660
[TBL] [Abstract][Full Text] [Related]
20. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.
Newman CB; Preiss D; Tobert JA; Jacobson TA; Page RL; Goldstein LB; Chin C; Tannock LR; Miller M; Raghuveer G; Duell PB; Brinton EA; Pollak A; Braun LT; Welty FK;
Arterioscler Thromb Vasc Biol; 2019 Feb; 39(2):e38-e81. PubMed ID: 30580575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
